Search
SOLACI Congress
HomePeripheral vascular diseaseRenal

Renal

View Category

Peripheral vascular disease

SYMPLICITY HTN-3 Trial. Evolution at 3 Years

The SYMPLICITY 3-year outcomes are out. Bear in mind this is the largest study we have had...
solaci -
Learn More
Peripheral vascular disease

TCT 2022 | RADIANCE II Pivotal Trial

Renal denervation has been developed to treat blood hypertension. Even though at present is still not common,...
solaci -
Learn More
Acute coronary syndromes

Gender Differences and 10-Year Prognosis in STEMI

Coronary artery disease in women usually develops 10 years later than in men, and some evidence suggests...
solaci -
Learn More
Peripheral vascular disease

RADIANCE-HTN SOLO: Control Durability of BP

In patients with hard-to-control high blood pressure (HBP), both non-pharmacological treatment and lifestyle changes have been useful...
solaci -
Learn More
Peripheral vascular disease

Renal Guard System to Prevent Contrast Induced Acute Kidney Injury in Patients at High Risk Contrast Induced Acute Kidney Injury

Contrast Induced Acute Kidney Injury (CI-AKI) is associated to increased costs and unfavorable results after hemodynamic procedures....
solaci -
Learn More
Peripheral vascular disease

EuroPCR 2022 | Renal denervation increases long-term time in target blood pressure range compared with sham control

Most hypertensive patients do not reach target blood pressure level ranges despite optimal medical treatment. Regardless anti-hypertensive...
solaci -
Learn More
Chronic Ischemic cardiopathy

In Multivessel Disease, When Should Renal Impairment Be Considered?

Cardiovascular disease is one of the main causes of morbidity and mortality in patients with advanced chronic...
solaci -
Learn More
Peripheral vascular disease

ACC 2022 | SPYRAL HTN-ON: Is It Time to Start Using Renal Denervation?

Thirty-eight patients were enrolled in the renal denervation (RDN) group, and 42 in the control group.  The mean...
solaci -
Learn More

SOLACI is the reference organization for Latin American cardiovascular interventionism.

Last News

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Dr. Andrés Rodríguez - 0
Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

Endovascular Treatment of Iliofemoral Disease for the Improvement of Heart Failure with Preserved Ejection Fraction

Dr. Omar Tupayachi - 0
Peripheral artery disease (PAD) is a significant risk factor in the development of difficult-to-treat conditions, such as heart failure with preserved ejection fraction (HFpEF)....

Coronary Artery Disease in Aortic Stenosis: CABG + SAVR vs. TAVR + PCI: Data from Spanish Centers

Dr. Omar Tupayachi - 0
Multiple randomized studies have shown comparable or superior efficacy of transcatheter aortic valve replacement (TAVR) vs. coronary artery bypass graft (CABG).  However, many of...

Institutional News

Check out the best images of the El Salvador 2024 Sessions

solaci - 0
Review the highlights of the XLIX SOLACI Regional Sessions held at the Intercontinental Hotel in San Salvador, El Salvador between November 7 and 8,...

The El Salvador 2024 Sessions are coming soon

solaci - 0
The XLIX SOLACI 2024 Regional Sessions (17th Central America & the Caribbean) are approaching, and will take place in the city of San Salvador (El Salvador)....

Check out the best images of the Arequipa 2024 Sessions

solaci - 0
Review the highlights of the XVIII SOLACI Regional Sessions held at the Hanan Hotel in Arequipa, Peru between October 3 and 4, 2024. <!-- wp:tw/bwg...

Access

Adolfo Alsina 2653 · Piso 2H · CABA · Buenos Aires · Argentina · (5411) 4954 7173 · info@solaci.org · solaci.org · Terms of Use -Privacy Policy